Research programme: biosimilars - JHL Biotech

Drug Profile

Research programme: biosimilars - JHL Biotech

Alternative Names: Denosumab biosimilar - JHL Biotech; JHL 1147; JHL 1188; JHL 1199; JHL 1211; JHL 1227; JHL 1266; Omalizumab biosimilar - JHL Biotech; Pertuzumab biosimilar - JHL Biotech; Trastuzumab biosimilar - JHL Biotech

Latest Information Update: 28 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator JHL Biotech
  • Class Antiallergics; Antiasthmatics; Antineoplastics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Osteoporosis therapies; Skin disorder therapies
  • Mechanism of Action Dimerisation inhibitors; ERBB 2 receptor antagonists; IgE receptor antagonists; Immunomodulators; Immunosuppressants; RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Allergic asthma; Bone cancer; Bone disorders; Gastric cancer; Osteoporosis; Urticaria
  • No development reported Breast cancer
  • Discontinued Autoimmune disorders; Cystic fibrosis

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for preclinical development in Breast-cancer in Taiwan (Parenteral)
  • 20 Apr 2018 Discontinued - Preclinical for Autoimmune disorders in Taiwan (unspecified route)
  • 20 Apr 2018 Discontinued - Preclinical for Cystic fibrosis in Taiwan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top